NeuroVista Corporation was an early-stage medical device company pioneering new technologies that will revolutionize the management and treatment of epilepsy, a neurological condition affecting approximately 1% of the U.S. population—more than Parkinson's disease, multiple sclerosis and Lou Gehrig's disease combined.
Cognition Labs, recognizing the wide neurodiversity of the human population, designs and creates software to enhance, support and supplement reading skills for the millions of people with differences in visual, auditory or other perceptual domains.